美国批准默克的埃博拉病毒预防疫苗上市

2019-12-24 不详 MedSci原创

美国监管机构已经批准了默克的Ervebo(rVSVΔG-ZEBOV-GP),这是首款在美国获得市场批准的埃博拉病毒(EVD)预防疫苗。

美国监管机构已经批准了默克的Ervebo(rVSVΔG-ZEBOV-GP),这是首款在美国获得市场批准的埃博拉病毒(EVD)预防疫苗。

该疫苗是由加拿大国家微生物学实验室在美国政府生物医学高级研究与发展局(BARDA)的资助下开发的,专门针对Zaire埃博拉病毒进行防护,可用于18岁及以上的个人。

"埃博拉疫苗获得FDA批准是埃博拉防备和预防工作的重要里程碑,"防备和应对措施副部长助理,BARDA主任里克·布莱特(Rick Bright)说。

默克公司表示,它正在努力启动许可剂量的生产,预计这些疫苗将在2020年第三季度左右开始提供。

该公司还与美国政府,世卫组织,联合国儿童基金会和Gavi(疫苗联盟)合作,"以计划最终支持未来的公共卫生防范和应对Zaire埃博拉病毒"。

欧盟委员会上个月批准了该疫苗。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1820141, encodeId=0afe1820141d7, content=<a href='/topic/show?id=143c100349b0' target=_blank style='color:#2F92EE;'>#预防疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100349, encryptionId=143c100349b0, topicName=预防疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Sun Jan 19 04:33:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650381, encodeId=7902165038121, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Thu Feb 27 20:33:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055046, encodeId=ad14205504645, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu May 28 17:33:00 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377446, encodeId=2d383e7446ea, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Dec 26 08:13:48 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273934, encodeId=477912e393434, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296485, encodeId=e2151296485fc, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402577, encodeId=254914025e729, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1820141, encodeId=0afe1820141d7, content=<a href='/topic/show?id=143c100349b0' target=_blank style='color:#2F92EE;'>#预防疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100349, encryptionId=143c100349b0, topicName=预防疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Sun Jan 19 04:33:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650381, encodeId=7902165038121, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Thu Feb 27 20:33:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055046, encodeId=ad14205504645, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu May 28 17:33:00 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377446, encodeId=2d383e7446ea, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Dec 26 08:13:48 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273934, encodeId=477912e393434, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296485, encodeId=e2151296485fc, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402577, encodeId=254914025e729, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1820141, encodeId=0afe1820141d7, content=<a href='/topic/show?id=143c100349b0' target=_blank style='color:#2F92EE;'>#预防疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100349, encryptionId=143c100349b0, topicName=预防疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Sun Jan 19 04:33:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650381, encodeId=7902165038121, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Thu Feb 27 20:33:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055046, encodeId=ad14205504645, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu May 28 17:33:00 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377446, encodeId=2d383e7446ea, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Dec 26 08:13:48 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273934, encodeId=477912e393434, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296485, encodeId=e2151296485fc, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402577, encodeId=254914025e729, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1820141, encodeId=0afe1820141d7, content=<a href='/topic/show?id=143c100349b0' target=_blank style='color:#2F92EE;'>#预防疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100349, encryptionId=143c100349b0, topicName=预防疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Sun Jan 19 04:33:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650381, encodeId=7902165038121, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Thu Feb 27 20:33:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055046, encodeId=ad14205504645, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu May 28 17:33:00 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377446, encodeId=2d383e7446ea, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Dec 26 08:13:48 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273934, encodeId=477912e393434, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296485, encodeId=e2151296485fc, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402577, encodeId=254914025e729, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=)]
    2019-12-26 thm112988

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1820141, encodeId=0afe1820141d7, content=<a href='/topic/show?id=143c100349b0' target=_blank style='color:#2F92EE;'>#预防疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100349, encryptionId=143c100349b0, topicName=预防疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Sun Jan 19 04:33:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650381, encodeId=7902165038121, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Thu Feb 27 20:33:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055046, encodeId=ad14205504645, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu May 28 17:33:00 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377446, encodeId=2d383e7446ea, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Dec 26 08:13:48 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273934, encodeId=477912e393434, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296485, encodeId=e2151296485fc, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402577, encodeId=254914025e729, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1820141, encodeId=0afe1820141d7, content=<a href='/topic/show?id=143c100349b0' target=_blank style='color:#2F92EE;'>#预防疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100349, encryptionId=143c100349b0, topicName=预防疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Sun Jan 19 04:33:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650381, encodeId=7902165038121, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Thu Feb 27 20:33:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055046, encodeId=ad14205504645, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu May 28 17:33:00 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377446, encodeId=2d383e7446ea, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Dec 26 08:13:48 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273934, encodeId=477912e393434, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296485, encodeId=e2151296485fc, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402577, encodeId=254914025e729, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1820141, encodeId=0afe1820141d7, content=<a href='/topic/show?id=143c100349b0' target=_blank style='color:#2F92EE;'>#预防疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100349, encryptionId=143c100349b0, topicName=预防疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Sun Jan 19 04:33:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650381, encodeId=7902165038121, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Thu Feb 27 20:33:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055046, encodeId=ad14205504645, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Thu May 28 17:33:00 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377446, encodeId=2d383e7446ea, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu Dec 26 08:13:48 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273934, encodeId=477912e393434, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296485, encodeId=e2151296485fc, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402577, encodeId=254914025e729, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=)]

相关资讯

lebrikizumab获得FDA快速通道资格用以治疗特应性皮炎

Dermira制药公司近日宣布,FDA已经授予lebrikizumab快速通道资格,用于治疗中度至重度特应性皮炎患者。Dermira首席执行官Tom Wiggans表示:“如果在进行中的III期研究中证实了II期研究的结果,那么这种快速通道资格将加快lebrikizumab的上市”。

Zotiraciclib治疗胶质母细胞瘤被FDA和EMA授予孤儿药称号

Zotiraciclib用于治疗胶质母细胞瘤,已被美国食品和药物管理局(FDA)和欧洲药品管理局(EMA)授予孤儿药指定(ODD)。该药物的指定是基于两项Ib期胶质母细胞瘤的临床研究。

Xtandi成**获批FDA 前列腺癌口服疗法

今日,安斯泰来(Astellas)和辉瑞(Pfizer)公司宣布,美国FDA批准Xtandi(enzalutamide)扩展适应症,治疗转移性激素敏感性前列腺癌(mHSPC)患者。新闻稿指出,这一批准,让Xtandi成为首款获得FDA批准,治疗三种不同形态晚期前列腺癌(非转移性和转移性去势抵抗性前列腺癌,和转移性去势敏感性前列腺癌)的口服疗法。

FDA专家组投票赞成,批准Keytruda治疗难治性膀胱癌

在FDA专家小组的投票之后,默克(Merck)的检查点抑制剂PD-1单抗Keytruda在美国获批了新的适应症--早期膀胱癌的治疗。

FDA批准了诺华多发性硬化症药物Gilenya的仿制药

FDA批准Sun制药、Biocon和HEC Pharm公司针对诺华的Gilenya(芬戈莫德)的首个仿制药营销申请,用于治疗成人复发型多发性硬化症(MS)。

百时美施贵宝宣布向FDA申请其CAR-T细胞疗法liso-cel的许可

百时美施贵宝公司今天宣布向美国食品药品监督管理局(FDA)提交其CAR-T细胞疗法lisocabtagene maraleucel(liso-cel)的生物许可证申请(BLA)。